Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | HTT | P42858 | 5/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31162406 | 0.90 | MAPT (0.58) | MAPTHTTTDP1GAAL3MBTL1 | |
| SCHEMBL246756 | 0.90 | MAPT (0.58) | MAPTHTTTDP1GAAL3MBTL1 | |
| SCHEMBL7106466 | 0.84 | MAPT (0.54) | MAPTHTTTDP1GAAL3MBTL1 | |
| SCHEMBL31451862 | 0.84 | MAPT (0.54) | MAPTHTTTDP1GAAL3MBTL1 | |
| SCHEMBL6212179 | 0.80 | MAPT (0.52) | MAPTHTTTDP1GAAL3MBTL1 | |
| SCHEMBL11817125 | 0.78 | MAPT (0.64) | MAPTHTTTDP1GAAL3MBTL1 | |
| SCHEMBL4020385 | 0.73 | KMT2A (0.55) | MAPTHTTTDP1GAAL3MBTL1 | |
| SCHEMBL5355239 | 0.71 | AXL (0.51) | ALDH1A1KMT2AMEN1AXLRXFP1 | |
| SCHEMBL5921938 | 0.71 | CTSB (0.61) | MAPTHTTTDP1GAAL3MBTL1 | |
| SCHEMBL6973083 | 0.71 | MAPT (0.56) | MAPTHTTTDP1GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6197771-B1 | NERVOUS SYSTEM DISORDERS; ANTIISCHEMIC AGENTS; ALZHEIMER'SDISEASE; PARKINSON'S DISEASE; HUNTINGTON'S DISEASE | WARNER-LAMBERT COMPANY | 2001-03-06 | — | — | US | disclosed |
| US-6057313-A | TREATING CENTRAL NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY (US) | 2000-05-02 | — | — | US | disclosed |
| WO-1996028445-A1 | NOVEL GLUTAMATE (AMPA/KAINATE) RECEPTOR ANTAGONISTS: N-SUBSTITUTED FUSED AZACYCLOALKYLQUINOXALINEDIONES | WARNER-LAMBERT COMPANY (US) | 1996-09-19 | — | — | WO | disclosed |